On December 29, 2025, the "Management Specifications of Human Gastrointestinal Tumoroids Drug Sensitivity Screening" (DB36/T 2203—2025) was officially released. The standard was developed under the leadership of Academician Chen Ye-Guang's team, in collaboration with multiple medical and scientific research institutions.This achievement marks a significant "zero-to-one" breakthrough for Jiangxi Province in the field of gastrointestinal tumoroids drug sensitivity screening. It also represents a critical step forward in the pursuit of precision medicine innovation by the School of Basic Medical Sciences atNanchang University.

Gastrointestinal cancers are characterized by high incidence and mortality rates globally. Despite continuous advancements in treatment strategies, the five-year survival rate for patients remains below 10%. Traditional drug evaluation models struggle to quickly and effectivelysimulate the complexity and heterogeneity of gastrointestinal tumors, leading to significant differences in drug responses among patients.Therefore, there is an urgent need for more precise technical means to predict patient drug responses. The emergence of organoid technology has provided an effective solution to this issue.

Patient-derived gastrointestinal tumoroids can highly simulate the pathological features, genetic background, and drug response profiles of primary tumors. They not only effectively address the limitations of traditional tumor models but also provides a vital experimental platform and decision-making basis for individualized precision treatment.The newly released standard establishes unified norms for quality control, ethical review, and drug sensitivity screeningof gastrointestinal tumoroids, filling the gap in technical standardization in this field within Jiangxi Province and strongly promoting the translation of organoid technology into clinical applications.

As the core research group of the School of Basic Medical Sciences at Nanchang University, Academician Chen Ye-Guang’s team will continue to promote the R&D, and translational application of organoid technology. This work aims to support the popularization of precision medicine and contribute to the implementation of the "Healthy China" strategy.In the future, organoid technology is expected to play an increasingly critical role in precision oncology, bringing new breakthroughs to improve patient survival rates and treatment outcomes.